Dr Toby Eyre

Dr Toby Eyre
MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD (University of Newcastle)
Consultant Haematologist

Languages spoken


Expert in

 Lymphoma and patients with chronic lymphocytic leukaemia



51.7239071200697, -1.2145938932540707
Dr Toby Eyre is a substantive consultant haematologist at Oxford University Hospitals NHS Foundation Trust specialising in the management of lymphoid malignancies. He is considered a national expert in the management of patients with lymphoma and patients with chronic lymphocytic leukaemia. He has completed an MD Doctorate Thesis in early phase trials and biomarker studies in aggressive lymphoid disease in 2017. He completed his haematology training in the Oxford deanery between 2010 and 2017. He is an investigator on a number of national UK lymphoma and chronic lymphocytic leukaemia trials and has published nearly 70 peer-review articles on areas of lymphoma and CLL and has presented regularly at national and international conferences. He is a core member of the low grade lymphoma and elderly high grade lymphoma NCRI clinical studies group and a member of the BSCH guideline writing group for follicular lymphoma and post-transplantation lymphoproliferative disorders. He also has a strong interest in teaching and training and has completed a post-graduate Diploma in Medical Education. ​

Career positions

Current position(s)
  • Consultant Haematologist


  •  Oxford University
  •  Oxford University Hospitals

Expertise and interests

  •  Lymphoma and patients with chronic lymphocytic leukaemia
  • Lymphoma and lymphoprofilerative disorders
  • Chronic lymphocytic leukaemia

Professional association

  • MRCP (UK)
  • FRCPath (UK)
  • British society of haematology



  • Prognostication in Richter syndrome: context is everything. 2020 May 18
  • DPACE-based chemotherapy in the era of myeloma novel agents: a UK multicentre study. 2020 Apr 8
  • Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival. 2020 Mar 31
  • Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK inhibition as an Effective Strategy. Clin Cancer Res. 2020 Mar 20
  • Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients. PLoS One. 2020 Feb 21